Ascentage Pharma Group International has announced the successful closing of an offshore placement, resulting in net proceeds of approximately HKD1,492 million (around US$190.1 million). The placement involved the sale of 22 million ordinary shares by the Dajun Yang Dynasty Trust, an affiliate of the company's CEO, Dajun Yang. These shares were sold at a price of HKD68.60 per share. In connection with this transaction, Ascentage Pharma will issue 22 million new ordinary shares to the Vendor at the same price. This newly issued equity represents about 6.29% of the company's share capital prior to the placement. The company plans to use the proceeds to enhance commercialization efforts, expand global clinical development, and improve infrastructure and working capital for its global operations.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。